The reverse vaccinology - a contextual overview

IIOAB Journal

Volumn 2, Issue 4, 2011, Pages 8-15

  Santos, Anderson ^a   Ali, Amjad ^a   Barbosa, Eudes ^a   Silva, Artur ^b   Miyoshi, Anderson ^a   Barh, Debmalya ^c   Azevedo, Vasco ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^c Institute of Integrative Omics and Applied Biotechnology IIOAB   (India)

Author keywords

Exponential function; Exported proteins; Reverse vaccinology; Vaccine candidates; Vaccine variables chances

Indexed keywords

DNA VACCINE;

CELLULAR IMMUNITY; GENERAL AND MISCELLANEOUS PROCEDURES AND TECHNIQUES; GENETIC ANALYSIS; GLYCOBIOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; INTERMETHOD COMPARISON; LIPIDOMICS; MEDICAL RESEARCH; NONHUMAN; REVERSE VACCINOLOGY; REVIEW; SEQUENCE ANALYSIS; STRATEGIC PLANNING; VACCINE PRODUCTION;

EID: 79960317967     PISSN: 09763104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Rappuoli R. [2000] Reverse vaccinology. Curr Opin Microbiol 3:445-450.
2. Sibbald MJJB, van Dij JML. [2009] Secretome Mapping in Gram-Positive Pathogens. In Karl Wooldridge (ed.), Bacterial Secreted Protein: Secretory Mechanisms and Role in Pathogenesis. Caister Academic Press: 193-225.
3. Simeone R, Bottai D, Brosch R, et al. [2009] ESX/type VII secretion systems and their role in host-pathogen interaction. Curr Opin Microbiol 12:4-10.
4. Stavrinides J, McCann HC, Guttman DS, et al. [2008] Host-pathogen interplay and the evolution of bacterial effectors. Cell Microbiol 10:285-292.
5. Bhavsar AP, Guttman JA, Finlay BB, et al. [2007] Manipulation of host-cell pathways by bacterial pathogens. Nature 449:827-834.
6. Diaz Romero J, Outschoorn IM. [1994] Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clin Microbiol Rev 7:559-575.
7. Giuliani MM, Adu-Bobie J, Comanducci M, et al. [2006] A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103:10834-10839.
8. Bambini S, Rappuoli R. [2009] The use of genomics in microbial vaccine development. Drug Discov Today 14:252-260.
9. Barinov A, Loux V, Hammani A, et al. [2009] Prediction of surface exposed proteins in Streptococcus pyogenes, with a potential application to other Gram-positive bacteria. Proteomics 9:61-73.
10. Yang H, Zhu Y, Qin J, et al. [2006] In silico and microarray-based genomic approaches to identifying potential vaccine candidates against Leptospira interrogans. BMC Genomics 7:293.
11. Taylor PD, Attwood TK, Flower DR, et al. [2006] Combining algorithms to predict bacterial protein sub-cellular location: Parallel versus concurrent implementations. Bioinformation 1:285-289.
12. Taylor PD, Toseland CP, Attwood TK, et al. [2006] TATPred: a Bayesian method for the identification of twin arginine translocation pathway signal sequences. Bioinformation 1:184-187.
13. Rinaudo CD, Telford JL, Rappuoli R, et al. [2009] Vaccinology in the genome era. J Clin Invest 119:2515-2525.
14. Lapierre P, Gogarten JP, [2009] Estimating the size of the bacterial pan-genome. Trends Genet 25:107-110.
15. Mendum TA, Newcombe J, McNeilly CL, et al. [2009] Towards the Immunoproteome of Neisseria meningitidis PLoS ONE 4:.
16. Rappuoli R. [2001] Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19:2688-2691.
17. Choi G, Eom S, Jung K, et al. [2010] CysA2: A candidate serodiagnostic marker for Mycobacterium tuberculosis infection. Respirology 15:636-642.
18. Cifuentes DP, Ocampo M, Curtidor H, et al. [2010] Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: potential TB vaccine candidate antigen. BMC Microbiol 10:109.
19. Gat O, Grosfeld H, Ariel N, et al. [2006] Search for Bacillus anthracis Potential Vaccine Candidates by a Functional Genomic-Serologic Screen. Infect Immun 74:3987-4001.
20. Dunachie SJ, Hill AVS, [2003] Prime-boost strategies for malaria vaccine development. J Exp Biol 206:3771-3779.
21. Al-Attiyah R, Mustafa AS. [2010] Characterization of human cellular immune responses to Mycobacterium tuberculosis proteins encoded by genes predicted in RD15 genomic region that is absent in Mycobacterium bovis BCG. FEMS Immunol Med Microbiol 59:177-187.
22. Dye C, Williams BG. [2010] The Population Dynamics and Control of Tuberculosis. Science 328:856-861.
23. Cole ST, Brosch R, Parkhill J, et al. [1998] Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
24. Cole ST, Barrell BG. [1998] Analysis of the genome of Mycobacterium tuberculosis H37Rv. Novartis Found Symp 217:160-72; discussion 172-7.
25. Vizcaíno C, Restrepo-Montoya D, Rodríguez D, et al. [2010] Computational prediction and experimental assessment of secreted/surface proteins from Mycobacterium tuberculosis H37Rv. PLoS Comput Biol 6:e1000824.
26. Shanahan ER, Pinto R, Triccas JA, et al. [2010] Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. Vaccine 28:1341-1346.
27. Bashir N, Kounsar F, Mukhopadhyay S, et al. [2010] Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions. Immunology 130:34-45.
28. Gaseitsiwe S, Valentini D, Mahdavifar S, et al. [2010] Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Clin Vaccine Immunol 17:168-175.
29. Romero IC, Mehaffy C, Burchmore RJ, et al. [2010] Identification of promoter-binding proteins of the fbp A and C genes in Mycobacterium tuberculosis Tuberculosis (Edinb) 90:25-30.
30. Nash JH, Findlay WA, Luebbert CC, et al. [2006] Comparative genomics profiling of clinical isolates of Aeromonas salmonicida using DNA microarrays. BMC Genomics 7:43.
31. Davila J, Zhang L, Marrs CF, et al. [2010] Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4. J Biomed Biotechnol 2010:208371.
32. Theodoridou MN, Vasilopoulou VA, Atsali EE, et al. [2007] Meningitis registry of hospitalized cases in children: epidemiological patterns of acute bacterial meningitis throughout a 32-year period. BMC Infect Dis 7:101.
33. Pizza M, Scarlato V, Masignani V, et al. [2000] Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820.
34. Madico G, Welsch JA, Lewis LA, et al. [2006] The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance. J Immunol 177:501-510.
35. Montor WR, Huang J, Hu Y, et al. [2009] Genome-Wide Study of Pseudomonas aeruginosa Outer Membrane Protein Immunogenicity Using Self-Assembling Protein Microarrays. Infect Immun 77:4877-4886.
36. Beernink PT, Welsch JA, Harrison LH, et al. [2007] Prevalence of Factor H-Binding Protein Variants and NadA among Meningococcal Group B Isolates from the United States: Implications for the Development of a Multicomponent Group B Vaccine. J Infect Dis 195:1472-1479.
37. Lipsitch M, O'Hagan JJ. [2007] Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface 4:787-802.
38. Brehony C, Wilson DJ, Maiden MC, et al. [2009] Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155:4155-4169.
39. Serruto D, Spadafina T, Ciucchi L, et al. [2010] Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 107:3770-3775.
40. Kuklin NA, Clark DJ, Secore S, et al. [2006] A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74:2215-2223.
41. Ventura CL, Malachowa N, Hammer CH, et al. [2010] Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS ONE 5:e11634.
42. Herron-Olson L, Fitzgerald JR, Musser JM, et al. [2007] Molecular correlates of host specialization in Staphylococcus aureus. PLoS ONE 2:e1120.
43. McCarthy AJ, Lindsay JA. [2010] Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol 10:173.
44. Otto M. [2010] Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther 10:1049-1059.
45. Holtfreter S, Kolata J, Bröker BM, et al. [2010] Towards the immune proteome of Staphylococcus aureus-The anti-S. aureus antibody response. Int J Med Microbiol 300:176-192.
46. Stranger-Jones YK, Bae T, Schneewind O, et al. [2006] Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103:16942-16947.
47. Mackey-Lawrence NM, Potter DE, Cerca N, et al. [2009] Staphylococcus aureus immunodominant surface antigen B is a cell-surface associated nucleic acid binding protein. BMC Microbiol 9:61.
48. Agnew J. [2010] Medicine in the Old West: A History, 1850-1900. McFarland
49. World Healt Organization [2010] Diphtheria [http://www.who.int/immunization/topics/diphtheria/en/index.html]
50. Wagner K, Stickings P, White J, et al. [2009] A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. Vaccine 28:14-20.
51. Dittmann S, Wharton M, Vitek C, et al. [2000] Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J Infect Dis 181 Suppl 1:S10-22.
52. Cerdeño-Tárraga AM, Efstratiou A, Dover LG, et al. [2003] The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129. Nucleic Acids Res 31:6516-6523.
53. Hansmeier N, Chao T, Kalinowski J, et al. [2006] Mapping and comprehensive analysis of the extracellular and cell surface proteome of the human pathogen Corynebacterium diphtheriae. Proteomics 6:2465-2476.
54. Iwaki M, Komiya T, Yamamoto A, et al. [2010] Genome organization and pathogenicity of Corynebacterium diphtheriae C7(-) and PW8 strains. Infect Immun 78:3791-3800.
55. Kang HJ, Paterson NG, Gaspar AH, et al. [2009] The Corynebacterium diphtheriae shaft pilin SpaA is built of tandem Ig-like modules with stabilizing isopeptide and disulfide bonds. Proc Natl Acad Sci U S A 106:16967-16971.
56. Mandlik A, Swierczynski A, Das A, et al. [2007] Corynebacterium diphtheriae employs specific minor pilins to target human pharyngeal epithelial cells. Mol Microbiol 64:111-124.
57. Telford JL, Barocchi MA, Margarit I, et al. [2006] Pili in gram-positive pathogens. Nat Rev Microbiol 4:509-519.
58. Proft T, Baker EN. [2009] Pili in Gram-negative and Gram-positive bacteria-structure, assembly and their role in disease. Cell Mol Life Sci 66:613-635.
59. Romney MG, Roscoe DL, Bernard K, et al. [2006] Emergence of an invasive clone of nontoxigenic Corynebacterium diphtheriae in the urban poor population of Vancouver, Canada. J Clin Microbiol 44:1625-1629.
60. Gubler J, Huber-Schneider C, Gruner E, et al. [1998] An outbreak of nontoxigenic Corynebacterium diphtheriae infection: single bacterial clone causing invasive infection among Swiss drug users. Clin Infect Dis 27:1295-1298.
61. Patey O, Bimet F, Riegel P, et al. [1997] Clinical and molecular study of Corynebacterium diphtheriae systemic infections in France. Coryne Study Group. J Clin Microbiol 35:441-445.
62. Health Protection Agency. [2006] Diphtheria Notifications and Deaths: England and Wales 1986-2006. [http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Diphtheria/EpidemiologicalData/]